PetIQ Company

PetIQ is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield. It distributes the products through veterinarian, retail and e-commerce channels. The Company offers its products in a range of categories, including Rx Medications, OTC Medications and Supplies, and Health and Wellness Products. Rx Medications offering includes heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics and other specialty medications. The Company manufactures Heart Shield Plus, version of Heartgard Plus, which prevents heartworm infection in dogs. The Company also manufactures TruProfen, the version of Rimadyl, which treats arthritis in dogs. OTC Medications and Supplies include flea and tick control products.
Technology: Physical Rehabilitation
Industry: P4 Medicine
Headquarters: Eagle, Idaho, United States
Zip: 251-500
Founded Date: 2010-01-01
Employees Number: 251-500
Funding Status: IPO
Acquisitions Number: 1
Investors Number: 1
Total Funding: $500M to $1B
Estimated Revenue: 2017-07-20
Last Funding Date: Venture - Series Unknown
Last Funding Type: info@truescience.com

Visit Website
http://twitter.com/truescience
https://www.crunchbase.com/organization/petiq
Register and Claim Ownership